753792
Last Update Posted: 2011-06-02
Recruiting has ended
All Genders accepted | 18 Years-59 Years |
49 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse
This is a phase IV, multicenter, randomized, double blind clinical trial. The investigators will study 48 patients with remitting relapsing multiple sclerosis (MS) experiencing moderate or severe attack receiving immunomodulatory therapy or not. Patients will be randomly assigned to one of the two groups.
This is a multicenter, randomized, double blind clinical trial to test whether oral methylprednisolone (MP) is not inferior to intravenous methylprednisolone for the treatment of multiple sclerosis (MS) relapse in terms of clinical and radiological efficacy.
Patients will be randomly assigned to one of the following two groups.
Group A: methylprednisolone 1.000 mg/day intravenous administered during three days + placebo of methylprednisolone orally administered
Group B: methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenously administered.
Clinical visits will be conducted at 7, 28 and 90 days after treatment starting.
Eligibility
Relevant conditions:
Multiple Sclerosis
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov